Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Omeros Corp OMER

Healthcare
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Recent & Breaking News (NDAQ:OMER)

Omeros to Present at the Cantor Virtual Global Healthcare Conference

Business Wire September 11, 2020

Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients

Business Wire September 3, 2020

Omeros' Investigational New Drug Application for OMS906 Cleared by FDA

Business Wire August 31, 2020

Omeros Announces Pricing of Public Offerings

Business Wire August 12, 2020

Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes

Business Wire August 10, 2020

Omeros Corporation Reports Second Quarter 2020 Financial Results

Business Wire August 10, 2020

Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

Business Wire August 10, 2020

Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress

Business Wire June 12, 2020

Omeros' Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress

Business Wire June 11, 2020

Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress

Business Wire May 14, 2020

Omeros Corporation Reports First Quarter 2020 Financial Results

Business Wire May 11, 2020

Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020

Business Wire May 5, 2020

Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results

Business Wire March 2, 2020

Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

Business Wire March 2, 2020

Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020

Business Wire February 24, 2020

Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors

Business Wire February 11, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

GlobeNewswire February 3, 2020

myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab

Business Wire December 18, 2019

Omeros' Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors

Business Wire December 16, 2019

Omeros Announces Full Exercise and Closing of Underwriter's Option to Purchase Additional Shares

Business Wire December 13, 2019